Michelle Dipp

Last updated

Michelle Dipp
Education MD PhD
Alma mater Brasenose College, Oxford University
SpouseBill Detwiler (2021–current) [1]
Parents
  • Mike Dipp, Jr. (father)
  • Mary Ann Dipp (mother)
Website https://michelle-dipp.com/

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti. [2]

Contents

Early life and education

Michelle Dipp was raised in El Paso, Texas. [3] Her mother was a nurse in the ER and her father was a businessman. [4]

Dipp attended Loretto Academy, where she graduated in 1994. [5] She graduated with a bachelor's degree, an M.D., and a Ph.D. in physiology from Oxford University. [4] [6]

Career

After graduation, Dipp moved to Boston, Massachusetts. In 2005, she began working at Sirtris Pharmaceuticals, a startup that created drugs that were meant to slow aging and protect against degenerative diseases related to aging. The company researched and tested activators of sirtuin, such as resveratrol formulations. [3] [7] In 2008, she became vice president of corporate development at Sirtris Pharmaceuticals. [4] [8]

Sirtris was purchased and made a subsidiary of GlaxoSmithKline in 2008. [9] At GlaxoSmithKline, Dipp became the head of their Center of Excellence for External Drug Discovery. [6]

2008–2010

In 2008, Dipp worked with Christoph Westphal, Richard Aldrich, and Alexey Margolin to found Alnara Pharmaceuticals, which was created to develop ways to formulate biopharmaceuticals so they could be taken by mouth, instead of by injection. [10]

In February 2010, Dipp, Westphal, and Aldrich formed a new venture fund called Longwood Founders Fund. In August 2010, the Longwood team co-founded VeraStem by providing seed funding and office space its offices; Verastem aimed to isolate cancer stem cells and then discover drugs that would selectively kill them. The company held its IPO in 2012. [11]

2015–2020

In January 2015 Longwood and Dipp helped found Flex Pharma [12] In November 2016 Dipp and Longwood helped launch Axial Biotherapeutics where she took a board seat. [13] In October 2017 Dipp became the Managing Director at General Atlantic, [14] [12] a global growth equity firm based in New York City. Michelle launched their first life sciences investment platform and served as a member of the life sciences investment committee while at General Atlantic. Michelle served as a Board Observer for Ginkgo BioWorks and as a board member for PathAI and Immunocore. [15]

In 2020, Dipp founded Biospring Partners with Jennifer Lum to conduct venture capital in the life sciences industry. Investments for Biospring Partners include funding for Abzena [16] who were subsequently selected to work on the antibody cocktail for COVID 19 treatment. [17] On June 30, 2020, the Securities and Exchange Commission announced that Michelle Dipp, a co-founder and former CEO of the now defunct OvaScience, Inc., agreed to settle fraud charges for misleading investors about the availability and commercial prospects for the company’s fertility treatments that were in development. [18]

Awards and honors

Related Research Articles

<span class="mw-page-title-main">GSK plc</span> UK healthcare company

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

<span class="mw-page-title-main">Human Genome Sciences</span> Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">David A. Sinclair</span> Australian geneticist (born 1969)

David Andrew Sinclair is an Australian-American biologist and academic known for his research and controversial claims on aging and epigenetics. Sinclair is a professor of genetics at Harvard Medical School.

<span class="mw-page-title-main">Andrew Witty</span> British business executive (born 1964)

Sir Andrew Philip Witty is a British business executive, who is the chief executive officer (CEO) of UnitedHealth Group. He was the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.

Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and Andrew Perlman, and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab.

Christoph Westphal is an American biomedical businessman.

The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.

<span class="mw-page-title-main">Santaris Pharma</span> Biopharmaceutical company founded in Denmark

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $450 million in March 2022, after raising its Opportunity Fund II totaling $300 million in September 2021.

Francesco De Rubertis is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016. Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm's efforts to establish its life sciences practice after joining in 1997.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.

<span class="mw-page-title-main">Amicus Therapeutics</span> Pharmaceutical company

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. The company went public in 2007 under the NASDAQ trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Emma Walmsley</span> British businesswoman

Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.

OvaScience was a publicly traded biotechnology company, focused on female infertility. It was founded in 2011 by Michelle Dipp, Richard Aldrich, Christoph Westphal, Jonathan Tilly, and David Sinclair and is based on scientific work done by Tilly concerning mammalian oogonial stem cells and work on mitochondria by Sinclair. Tilly's work was expectedly met with skepticism, as it warranted a paradigm-shift; however, many labs across the world have been able to reproduce his results over several decades.

Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

<span class="mw-page-title-main">Moncef Slaoui</span> Moroccan-American-Belgian doctor and researcher

Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.

<span class="mw-page-title-main">Peter Elliott (pharmacologist)</span> British pharmacologist (born 1958)

Peter Elliott is a British pharmacologist and drug developer who has initiated clinical trials across a range of disease areas, and is the co-developer of Velcade, a drug used to treat multiple myeloma.

References

  1. ↑ Dahl, Amanda (March 23, 2021). "Newly Engaged! Michelle Dipp & Bill Detwiler". STLtoday.com.
  2. ↑ "Biospring Partners | Michelle Dipp". Biospring Partners.
  3. 1 2 Kolenc, Vic. "El Pasoan a star in biotech industry". El Paso Times.
  4. 1 2 3 "El Paso native on Fortune '40 under 40'".
  5. ↑ Loretto Academy Alumnae Directory. El Paso, Texas: Harris Connect. 2010. p. 30.
  6. 1 2 3 "Michelle Dipp As the head of the U.S. for the Centre of Excellence for External Drug Discovery (CEEDD)".
  7. ↑ Wade, Nicholas (August 17, 2009). "Tests Begin on Drugs That May Slow Aging – The New York Times". The New York Times.
  8. ↑ "Dr. Michelle Dipp – Women in Biotech 2012". FierceBiotech. November 8, 2012.
  9. ↑ Pollack, Andrew (April 23, 2008). "Glaxo to buy Sirtris, maker of a drug based on red wine". The New York Times.
  10. ↑ Timmerman, Luke (October 30, 2008). "Alnara Pharmaceuticals Aims to Make Biotech Drugs You Can Swallow, And That Go Right Where They Belong".
  11. ↑ "Xconomy: Verastem Switches CEOs as Westphal Steps Into Chairman Role". Xconomy. June 6, 2013.
  12. 1 2 "Michelle Dipp Joins General Atlantic as Managing Director". October 12, 2017.
  13. ↑ "New Boston Biotech Axial Biotech Launches With $19.15 Million and Will be Helmed by AbbVie-GlaxoSmithKline Vet".
  14. ↑ "Dr. Michelle Dipp Joins General Atlantic as Managing Director".
  15. ↑ "PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst". www.businesswire.com. April 17, 2019.
  16. ↑ Louch, Laura Cooper and William (July 28, 2020). "Biospring Partners Backs Drug Developer and Manufacturer Abzena". Wall Street Journal– via www.wsj.com.
  17. ↑ "Abzena Selected by Immunome to Manufacture Antibody Cocktail for COVID-19 Treatment | Pharmaceutical Outsourcing – The Journal of Pharmaceutical & Biopharmaceutical Contract Services".
  18. ↑ "SEC Charges Former Biotechnology Company CEO for Misleading Investors". SEC.gov. June 30, 2020. Retrieved August 31, 2022.
  19. ↑ "40 under 40; Michelle Dipp-28". Fortune.com. 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.